Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma
Pivotal time of transition as the company prepares to start clinical development of its first-in-class lead candidate, AT-7687 in obesity
AT-7687 offers a new mechanism of action, to set a new standard in obesity management
Copenhagen, Denmark – January 8, 2025 – Antag Therapeutics (“Antag” or “the company”), a biopharmaceutical company pioneering novel treatments for obesity, today announced the appointment of Joerg Moeller, MD, PhD, as Chief Executive Officer, effective immediately. Dr. Moeller succeeds Antag’s Co-Founder and former CEO, Dr. Alexander Sparre-Ulrich, who played a pivotal role in reaching clinical inflection points and establishing Antag as a leader in GIP receptor antagonism, a new mechanism in the field of obesity. Dr. Sparre-Ulrich will move into the position of Chief Operating Officer and will continue to support the company in a senior role.
